Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Tubergen

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancer|April 7, 1998
Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group ExperienceP S Gaynon, R P Qu, R J Chappell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group reportD G Tubergen, G S Gilchrist, R T O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trialD G Tubergen, G S Gilchrist, R T O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group studyD G Tubergen, J W Cullen, J M Boyett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group reportG S Gilchrist, D G Tubergen, H N Sather, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group studyD G Tubergen, M D Krailo, A T Meadows, et al.
Clinical Chemistry|April 1, 1982
Two-dimensional gel electrophoresis of cell proteins in childhood leukemia, with silver staining: a preliminary reportS M Hanash, D G Tubergen, R M Heyn, et al.
Cancer|May 15, 1993
Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatmentJ Nachman, H N Sather, J D Buckley, et al.
Blood|July 1, 1997
Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer GroupF M Uckun, H N Sather, P S Gaynon, et al.
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer|April 7, 1998
Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group ExperienceP S Gaynon, R P Qu, R J Chappell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group reportD G Tubergen, G S Gilchrist, R T O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trialD G Tubergen, G S Gilchrist, R T O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group studyD G Tubergen, J W Cullen, J M Boyett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group reportG S Gilchrist, D G Tubergen, H N Sather, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group studyD G Tubergen, M D Krailo, A T Meadows, et al.
Clinical Chemistry|April 1, 1982
Two-dimensional gel electrophoresis of cell proteins in childhood leukemia, with silver staining: a preliminary reportS M Hanash, D G Tubergen, R M Heyn, et al.
Cancer|May 15, 1993
Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatmentJ Nachman, H N Sather, J D Buckley, et al.
Blood|July 1, 1997
Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer GroupF M Uckun, H N Sather, P S Gaynon, et al.
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Pageof 4